Absorbed dose verification in targeted radionuclide therapy

Background and purpose

Absorbed dose verification in targeted radionuclide therapy (TRT), particularly for 177Lu-based PSMA- and SSTR-targeted therapies, is increasingly discussed in clinical, scientific, and regulatory contexts. At the same time, current clinical practice across European nuclear medicine centres is highly heterogeneous, reflecting differences in patient volume, infrastructure, staffing, and local workflows.

This short survey constitutes Stage 1 of a two-stage EANM project initiative. Its purpose is to provide a high-level overview of:

·      current clinical activity in 177Lu-based TRT,

·      routine post-therapy imaging and dosimetry practice, and

·      the realistic capacity to perform additional dosimetry in a small patient subgroup.

Scope and nature of the survey

This is not a technical survey and not a guideline survey. It does not aim to assess how dosimetry should be performed, nor does it imply any obligation to contribute data or change clinical practice. The survey is designed to take approximately 5 minutes to complete.

Based on the responses, a second, more detailed assessment will be conducted in a limited number of interested and eligible centres. This staged approach is intended to ensure that any subsequent expert discussions, position papers, or guideline activities are grounded in clinical feasibility and reflect real-world European practice.

Thank you for taking a few minutes to participate! 

In case of any questions, feel free to contact the EANM office [email protected]